Ollin Biosciences Announces $330 Million Series B
· vcnewsdaily.com
AUSTIN, TX, Ollin Biosciences, a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, announced an oversubscribed $330 million Series B financing.
Ollin Biosciences Announces $330 Million Series B Back to Home
AUSTIN, TX, Ollin Biosciences, a clinical-stage biotech advancing best-in-disease therapies for ...